Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00648739 · MORE INFO

Limitations, agreements, and source contact

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM · Source last updated 2019-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Part B of the study was not conducted.
point Of Contact
email
clinicaltrials@alexion.com
organization
Alexion Pharmaceuticals Inc.
phone
855-752-2356
title
Alexion Pharmaceuticals Inc.
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Part B of the study was not conducted.
point Of Contact
email
clinicaltrials@alexion.com
organization
Alexion Pharmaceuticals Inc.
phone
855-752-2356
title
Alexion Pharmaceuticals Inc.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice